

DAFTAR PUSTAKA

- Billiet, L., Doaty, S., Katz, J. D. & Velasquez, M. T., 2014. Review of hyperuricemia as new marker for metabolic syndrome. *ISRN Rheumatology*, Volume 2014, pp. 1-7.
- Bing, R. & Dweck, M. R., 2019. Myocardial fibrosis: why image, how to image and clinical implications. *Heart*, 105(23), pp. 1832-1840.
- Chaudhary, K., Malhotra, K., Sowers, J. & Aroor, A., 2013. Uric acid - key ingredient in the recipe for cardiorenal metabolic syndrome. *Cardiorenal Medicine*, 3(3), pp. 208-220.
- Dapson, R., Fagan, C., Kiernan, J. & Wickersham, T., 2011. Certification procedures for sirius red F3B (CI 35780, Direct red 80). *Biotechnic & Histochemistry*, 86(3), pp. 133-139.
- Din, U. A. S. E., Salem, M. M. & Abdulazim, D. O., 2017. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: a review. *Journal of Advanced Research*, 8(5), pp. 537-548.
- Doehner, W. & Anker, S. D., 2005. Uric acid in chronic heart failure. *Seminars in Nephrology*, 25(1), pp. 61-66.
- George, J., Carr, E., Davies, J., Belch, J. J. F., Struthers, A., 2006. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. *Circulation*, 114(23), pp. 2508-2516.
- González, A., Schelbert, E. B., Díez, J. & Butler, J., 2018. Myocardial interstitial fibrosis in heart failure. *Journal of the American College of Cardiology*, 71(15), pp. 1696-1706.
- Gracia, K. C., Llanas-Cornejo, D. & Husi, H., 2017. CVD and oxidative stress. *Journal of Clinical Medicine*, 6(22), pp. 1-22.
- Gu, J., Fan, Y.-Q., Zhang, H.-L., Zhang, J.-F., Wang, C.-Q., 2018. Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension. *The Journal of Clinical Hypertension*, 20(3), pp. 560-567.
- Gustafsson, D. & Unwin, R., 2013. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. *BMC Nephrology*, 14(1), pp. 1-9.
- Hara, H., Takeda, N. & Komuro, I., 2017. Pathophysiology and therapeutic potential of cardiac fibrosis. *Inflammation and Regeneration*, 37(1), pp. 1-10.
- Haryono, A., Nugrahaningsih, D. A. A., Sari, D. C. R., Romi, M. M., Arfian, N., 2018. Reduction of serum uric acid associated with attenuation of renal injury, inflammation and macrophages m1/m2 ratio in hyperuricemic mice model. *Kobe Journal of Medical Sciences*, 64(3), pp. E107-E114.
- Iliesiu, A., Campenau, A. & Duceac, D., 2010. Serum uric acid and cardiovascular disease. *Maedica : Journal of Clinical Medicine*, 5(3), pp. 186-192.
- Jia, N., Dong, P., Ye, Y., Qian, C., Dai, Q., 2010. Allopurinol attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction. *Cardiovascular Therapeutics*, 2(30), pp. 117-123.

- Johnson, R. J. Sánchez-Lozada, L. G., Mazzali, M., Feig, D. I., Kanbay, M., Sautin, Y. Y., 2013. What are the key arguments against uric acid as a true risk factor for hypertension?. *Hypertension*, 5(61), pp. 948-951.
- Kanbay, M., Solak, Y., Gaipov, A., Takir, M., Weiner, D. E., 2014. Allopurinol as a kidney-protective, cardioprotective, and antihypertensive agent: hype or reality?. *Blood Purification*, 37(3), pp. 172-178.
- Kang, D.-H. & Ha, S.-K., 2014. Uric Acid Puzzle: Dual Role as Anti-oxidant and Pro-oxidant. *Electrolytes & Blood Pressure*, 12(1), pp. 1-6.
- Kang, L. L., Zhang, D. M., Ma, C. H., Zhang, J. H., Jia, K. K., Liu, J. H. *et al.*, 2016. Cinnamaldehyde and allopurinol reduce fructose-induced cardiac inflammation and fibrosis by attenuating CD36-mediated TLR4/6-IRAK4/1 signaling to suppress NLRP3 inflammasome activation. *Scientific Reports*, 6(1), pp. 1-18.
- Karim, B., Nasution, S. A., Wijaya, I. P. & Harimurti, K., 2015. Hyperuricemia as a risk factor of major adverse cardiac events in patient with acute coronary syndrome: a retrospective cohort study.. *Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine*, 47(4), pp. 320-325.
- Katsiki, N. & Mikhailidis, D. P., 2015. Hyperuricaemia in cardiovascular diseases: a passive or an active player?. *Medical Principles and Practice*, 24(3), pp. 269-270.
- Kemenkes, 2018. *Hasil utama Riskesdas 2018*, Jakarta: Balitbangkes Kemenkes RI.
- Khan, R. & Sheppard, R., 2006. Fibrosis in heart disease: understanding the role of transforming growth factor-beta1 in cardiomyopathy, valvular disease and arrhythmia. *Immunology*, 118(1), pp. 10-24.
- Kierszenbaum, A. L. & Tres, L., 2016. *Histology and cell biology : an introduction to pathology*. Fourth Edition ed. Canada: Elsevier.
- Kong, P., Christia, P. & Frangogiannis, N. G., 2013. The pathogenesis of cardiac fibrosis. *Cellular and Molecular Life Sciences*, 71(4), pp. 549-574.
- Kushiyaama, A., Nakatsu, Y., Matsunaga, Y., Yamamotoya, T., Mori, K., Ueda, K. *et al.*, 2016. Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis. *Mediators of Inflammation*, Volume 2016, pp. 1-15.
- Larsen, K. S., Pottgård, A., Lindegaard, H. M. & Hallas, J., 2016. Effect of allopurinol on cardiovascular outcomes in hyperuricemic patients: a cohort study. *The American Journal of Medicine*, 129(3), pp. 299-306.
- Liu, T., Song, D., Dong, J., Zhu, P., Liu, J., Liu, W. *et al.*, 2017. Current understanding of the pathophysiology of myocardial fibrosis and its quantitative assessment in heart failure. *Frontiers in Physiology*, Volume 8, pp. 1-13.
- Li, Z., Shen, Y., Chen, Y., Zhang, G., Cheng, J., Wang, W., 2018. High uric acid inhibits cardiomyocyte viability through the ERK/p38 pathway via oxidative stress. *Cellular Physiology and Biochemistry*, 45(3), pp. 1156-1164.

- MacIsaac, R. L., Salatzki, J., Higgins, P., Walters, M. R., Padmanabhan, S., Dominiczak, A. F. *et al.*, 2016. Allopurinol and cardiovascular outcomes in adults with hypertension. *Hypertension*, 67(3), pp. 535-540.
- Ma, Z.-G., Yuan, Y.-P., Wu, H.-M., Zhang, X., Tang, Q.-Z., 2018. Cardiac fibrosis: new insights into the pathogenesis. *International Journal of Biological Sciences*, 14(12), pp. 1645-1657.
- Mescher, A. L., 2013. *Junquera's basic histology text and atlas thirteenth edition*. New York: : McGraw-Hill Education.
- Mitsuhashi, H., Yatsuya, H., Matsushita, K., Zhang, H., Otsuka, R., Muramatsu, T. *et al.*, 2009. Uric acid and left ventricular hypertrophy in Japanese men. *Circulation Journal*, 73(4), pp. 667-672.
- Moore, K. L., Dalley, A. F. & Agur, A. M., 2014. *Moore clinically oriented anatomy seventh edition*. Philadelphia: Lippincott Williams & Wilkins.
- Muiesan, M. L., Agabiti-Rosei, C., Paini, A. & Salvetti, M., 2016. Uric acid and cardiovascular disease: an update. *European Cardiology Review*, 11(1), pp. 54-59.
- Nagao, K., Inada, T., Tamura, A., Kajitani, K., Shimamura, K., Yukawa, H. *et al.*, 2018. Circulating markers of collagen types I, III, and IV in patients with dilated cardiomyopathy: relationships with myocardial collagen expression. *ESC Heart Failure*, 5(6), pp. 1044-1051.
- Nagaraju, C. K., Robinson, E. L., Abdesselem, M., Trenson, S., Dries, E., Gilbert, G. *et al.*, 2019. Myofibroblast phenotype and reversibility of fibrosis in patients with end-stage heart failure. *Journal of the American College of Cardiology*, 73(18), pp. 2267-2282.
- Ricard-Blum, S., 2010. The collagen family. *Cold Spring Harbor Perspectives in Biology*, 3(1), pp. 1-19.
- Robertson, A. J. & Struthers, A. D., 2016. A randomized controlled trial of allopurinol in patients with peripheral arterial disease. *Canadian Journal of Cardiology*, Volume 32, pp. 190-196.
- Romi, M. M., Arfian, N., Tranggono, U., Setyaningsih, W. A. W., Sari, D. C. R., 2017. Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation. *BMC Nephrology*, 18(1), pp. 1-8.
- Sagor, M. A. T., Tabassum, N., Potol, M. A. & Alam, M. A., 2015. Xanthine oxidase inhibitor, allopurinol, prevented oxidative stress, fibrosis, and myocardial damage in isoproterenol induced aged rats. *Oxidative Medicine and Cellular Longevity*, Volume 2015, pp. 1-9.
- Singh, J. A., Ramachandaran, R., Yu, S. & Curtis, J. R., 2017. Allopurinol use and the risk of acute cardiovascular events in patients with gout and diabetes. *BMC Cardiovascular Disorders*, 17(1), pp. 1-9.
- Tian, J., An, X. & Niu, L., 2017. Myocardial fibrosis in congenital and pediatric heart disease. *Experimental and Therapeutic Medicine*, 13(5), pp. 1660-1664.
- Travers, J. G., Kamal, F. A., Robbins, J., Yutzey, K. E., Blaxall, B. C., 2016. Cardiac fibrosis. *Circulation Research*, 118(6), pp. 1021-1040.
- Verma, A. T. & Gin, K., 2016. Allopurinol in vascular disease: is there a new role for an old drug?. *Canadian Journal of Cardiology*, Volume 32, pp. 145-147.

- WHO, 2018. *World Health Organization - noncommunicable diseases country profile*. [Online]
Available at: https://www.who.int/nmh/countries/idn_en
- Yang, Y., Zhao, J., Qiu, J., Li, J., Liang, X., Zhang, Z. *et al.*, 2018. Xanthine oxidase inhibitor allopurinol prevents oxidative stress-mediated atrial remodeling in alloxan-induced diabetes mellitus rabbits. *Journal of the American Heart Association*, 7(10), pp. 1-15.
- Yan, M., Chen, K., He, L., Li, S., Huang, D., Li, J., 2018. Uric acid induces cardiomyocyte apoptosis via activation of calpain-1 and endoplasmic reticulum stress. *Cellular Physiology and Biochemistry*, 45(5), pp. 2122-2135.
- Zi, Z., Chapnick, D. A. & Liu, X., 2012. Dynamics of TGF- β /Smad signaling. *FEBS Letters*, 586(14), pp. 1921-1928.
- Zuo, T., Liu, X., Jiang, L., Mao, S., Yin, X., Guo, L., 2016. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. *BMC Cardiovascular Disorders*, 16(1), pp. 1-10.